Recruiting

Selective Lymph Node Removal Surgery for Early Lung Cancer in the Upper Lobe

Plain-English translation of NCT06031246 on ClinicalTrials.gov ↗ · Source last updated September 2023 · Translation generated August 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a surgical approach called selective lymph node dissection for patients with early-stage lung cancer (specifically adenocarcinoma) located in the upper part of the lung. Instead of removing all nearby lymph nodes, surgeons remove only the lymph nodes most likely to contain cancer. The trial wants to see if this approach works well and leads to good long-term survival.

For some early-stage lung cancers, removing all nearby lymph nodes may be more extensive than needed. This trial exists to see whether removing fewer, but strategically chosen, lymph nodes can be just as effective while potentially reducing surgery-related side effects.

Do you qualify?

You likely qualify if…

you are between 18 and 80 years old
you have been diagnosed with early-stage invasive lung adenocarcinoma in the upper lobe that has not spread to lymph nodes or other parts of your body
your tumor meets specific size and location criteria as confirmed by imaging
you have never had lung cancer surgery before
you have not received chemotherapy or radiation therapy before this surgery

You likely don't qualify if…

you have had previous lung cancer surgery
your tumor is located outside the upper lobe or does not meet the size requirements
you have already received chemotherapy or radiation therapy for any reason
your cancer has spread to lymph nodes or other parts of your body
you have a type of lung adenocarcinoma that is purely lepidic (a slow-growing pattern) or pre-invasive

What participation looks like

If you join this trial, you will undergo the selective lymph node dissection surgery as your treatment for lung cancer. After surgery, the research team will follow you over time—particularly for 5 years—to track your overall survival, check for any cancer recurrence, and monitor whether cancer spreads to lymph nodes. You will have regular follow-up visits and imaging tests as part of standard cancer care.

AI-generated summary from trial data · Aug 8, 2026 · Not medical advice

Trial locations(1 site)

China

Chaoqiang Deng, Shanghai, Please Select